^
    Back
    Association details:
    Biomarker:MGMT unmethylation
    Cancer:Glioblastoma
    Drug:dianhydrogalactitol (VAL-083) (Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Kintara Therapeutics Press Release
    Title:

    Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study

    Published date:
    11/19/2020
    Excerpt:
    ...two Phase 2 clinical trials evaluating VAL-083 in patients with MGMT-unmethylated GBM...In newly-diagnosed patients receiving VAL-083 as adjuvant therapy following treatment with radiation and TMZ, for the 27 efficacy evaluable patients (of a planned up to 36 patients) as of the data cut-off of October 23, 2020, median progression-free survival (PFS) is currently 10.0 months (confidence interval: CI 7.6-10.8).
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Neuro Oncol
    Title:

    PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: CASE STUDY REPORTS

    Published date:
    09/08/2023
    Excerpt:
    The first, a 32-yo woman, WHO Gr. 4 GBM (MGMT unmethylated), who received conventional radiotherapy with concurrent chemotherapy with VAL-083 followed by adjuvant VAL-083, for a total of 13 cycles of VAL-083. This patient is tumor free suvival more than 4 years till last follow-up (Mar 2023 ).
    DOI:
    https://doi.org/10.1093/neuonc/noad137.275